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Abstract
Background Lynch syndrome (LS), the most common inherited form of colorectal cancer (CRC), is responsible for 3% of 
all cases of CRC. LS is caused by a mismatch repair gene defect and is characterized by a high risk for CRC, endometrial 
cancer and several other cancers. Identification of LS is of utmost importance because colonoscopic surveillance substantially 
improves a patient’s prognosis. Recently, a network of physicians in Middle Eastern and North African (ME/NA) countries 
was established to improve the identification and management of LS families. The aim of the present survey was to evaluate 
current healthcare for families with LS in this region.
Methods A questionnaire was developed that addressed the following issues: availability of clinical management guidelines 
for LS; attention paid to family history of cancer; availability of genetic services for identification and diagnosis of LS; and 
assessment of knowledge of LS surveillance. Members of the network and authors of recent papers on LS from ME/NA and 
neighbouring countries were invited to participate in the survey and complete the online questionnaire.
Results A total of 55 individuals were invited and 19 respondents from twelve countries including Algeria, Azerbaijan, 
Cyprus, Egypt, Iran, Jordan, Kuwait, Lebanon, Morocco, Palestine, Tunisia, and Turkey completed the questionnaire. The 
results showed that family history of CRC is considered in less than half of the surveyed countries. Guidelines for the man-
agement of LS are available in three out of twelve countries. The identification and selection of families for genetic testing 
were based on clinical criteria (Amsterdam criteria II or Revised Bethesda criteria) in most countries, and only one country 
performed universal screening. In most of the surveyed countries genetic services were available in few hospitals or only 
in a research setting. However, surveillance of LS families was offered in the majority of countries and most frequently 
consisted of regular colonoscopy.
Conclusion The identification and management of LS in ME/NA countries are suboptimal and as a result most LS families 
in the region remain undetected. Future efforts should focus on increasing awareness of LS amongst both the general popula-
tion and doctors, and on the improvement of the infrastructure in these countries.
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Introduction
Colorectal cancer (CRC) is the third most commonly diag-
nosed cancer worldwide and the fourth leading cause of 
cancer-related death [1]. Although the incidence of CRC 
in Middle Eastern and North African (ME/NA) countries is 
low compared to Western countries [2], recent reports sug-
gest that it is increasing rapidly [3].
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One option for prevention of CRC is offering surveil-
lance to individuals at high risk of inherited CRC. The most 
common hereditary form of CRC is Lynch syndrome (LS), 
which is responsible for 3% of all cases of CRC [4]. LS is an 
autosomal dominant disorder caused by a pathogenic variant 
in one of the mismatch repair (MMR) genes, which include 
MLH1, MSH2 (EPCAM), MSH6 and PMS2. Loss of MMR 
function leads to the molecular phenotype of microsatellite 
instability (MSI) in tumours, which in turn drives carcino-
genesis [4].
LS is characterized by a very high risk of developing CRC 
and endometrial cancer. The risk of developing a metachro-
nous CRC is also high in Lynch syndrome individuals, 
therefore such patients should be offered a more extensive 
surgical treatment compared to sporadic CRC patients. LS 
families also show other cancers including cancers of the 
urinary tract, ovaries, stomach, pancreas, biliary tract, skin 
and cancers of the brain. Cancer risks and the spectrum of 
tumours depends on the type of underlying pathogenic vari-
ant [5]. The molecular phenotype of MSI characteristic for 
LS-associated tumours can be identified by PCR fragment 
length analysis of microsatellite markers or immunohisto-
chemical (IHC) analysis of the MMR proteins. The diagno-
sis is confirmed by analysis of germline DNA.
Several studies have demonstrated that periodic exami-
nation of the colon leads to an improved prognosis and a 
substantial decrease in mortality [6, 7]. Identification of LS 
and the participation of families in surveillance programs is 
therefore of paramount importance.
In 2017, at a conference of the Palestinian Society of Gas-
troenterology in Jericho, a new network of doctors interested 
in hereditary CRC in ME/NA countries was established, now 
referred to as the Hereditary Colorectal Cancer Network-
Middle East (HCCN-ME) [8]. The main goal of this network 
is to improve care for individuals with inherited CRC in 
these countries. In order to reach this goal, we first need a 
picture of current management of LS in the region. Thus, 
the aim of the present study was to survey the state of LS 
healthcare in ME/NA countries.
Methods
Our first task was to develop a questionnaire that addresses 
the most relevant issues (Supplementary file 1).The ques-
tionnaire contains three categories of questions: (1) general 
questions about the availability of guidelines for diagnosis 
and management of LS in each country, including ques-
tions concerning the attention paid by physicians to family 
histories of CRC (cancer), (2) questions about the genetic 
services available for the identification and diagnosis of LS, 
and (3) questions that assess general knowledge of the clini-
cal management of LS patients.
All members of the network, and authors of recent arti-
cles on LS from ME/NA or neighbouring countries, were 
invited to participate in the survey. The invitation mail con-
tained a link to the online questionnaire (developed using 
SurveyMonkey). The respondents came from 12 countries 
in the ME/NA region.
Results
A total of 22 (40%) out of 55 professionals invited to par-
ticipate in the survey responded. Three participants were 
excluded because they completed too few questions. The 
remaining 19 respondents were from twelve countries, 
including Algeria, Azerbaijan, Cyprus (two respondents), 
Egypt, Iran (two respondents), Jordan, Kuwait (two respond-
ents), Lebanon, Morocco, Palestine (four respondents), 
Tunisia (two respondents), and Turkey (Table 1).
The respondents included eight clinical/molecular geneti-
cists, four gastroenterologists, one surgeon, one researcher, 
one specialized nurse, one paediatrician, two biological sci-
entists and one pathologist. Twelve of the 19 respondents 
were affiliated to a University Medical Centre.
The survey revealed that guidelines for the diagnosis and 
management of LS were available in three countries. In two 
countries, the respondents were unaware of clinical guide-
lines in their country. In five countries, most doctors pay 
appropriate attention to family history of CRC.
Genetic services were available in a research setting in 
one country, in only a few hospitals in six countries, in sev-
eral hospitals in three countries and were absent in two coun-
tries. The most common explanation for the limited avail-
ability of these services was lack of funds in five countries, 
lack of interest or knowledge in four countries and a lack of 
trained geneticists in one country.
Table 1  Countries involved in 
the survey, including population 
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Where genetic services were available, pedigree analysis 
was offered in ten countries, genetic counselling in eight 
countries, IHC or MSI-analysis in eight countries, MLH1-
promotor methylation or BRAF-analysis of tumours (per-
formed to exclude methylation of the MLH1-promotor 
as cause of loss of MMR-function) in eight countries and 
(Sanger) sequencing or Next Generation Sequencing (NGS) 
in ten countries.
Clinical criteria were used for the identification of LS 
in eight of the 12 countries, while systematic screening 
of tumours was offered in only one country (i.e., Cyprus). 
Respondents from almost all countries (11 out of 12) stated 
that most LS families go unidentified in their country. By 
contrast, the respondent from Turkey reported that most LS 
patients in that country were identified.
With respect to the management of LS, colonoscopic sur-
veillance is offered in 11 out of 12 countries and surveillance 
of the endometrium in five of the 12 countries. As regards 
the less common cancers observed in LS, surveillance of 
the urinary tract is offered in three countries and upper GI 
tract in five countries. Assessment of H.pylori infection was 
performed in four of the 12 countries. Extended surgery 
(subtotal colectomy) for CRC diagnosed at < 50–60 years 
was an option in six of the 12 countries. A registry of fami-
lies with Lynch syndrome was available in seven out of the 
12 countries. The replies to five questions have not been 
shown because most respondents did not have information 
about the issue that was addressed. The outcome of the sur-
vey is summarized in Table 2.
Discussion
Lynch syndrome is an example of an inherited form of can-
cer for which surveillance and early treatment is extremely 
effective [6, 7]. It is one of the most common inherited forms 
of cancers, affecting approximately 1/300 people in Western 
countries [9]. Although data on the incidence of LS in Mid-
dle East and North African (ME/NA) countries are limited, 
studies suggest that LS accounts for a similar proportion of 
CRC compared to Western countries [10]. Based on these 
figures and an estimated population of 390 million in the 12 
countries covered in the survey, we estimate that more than 
one million individuals in these countries have LS.
Table 2  Main outcomes from 
survey on current Lynch 
syndrome healthcare in the 




1. Guidelines available for management of LS? 3
2. Appropriate attention to family history of CRC by most doctors? 5
3. Genetic services available:
   Several hospitals 3
   Few hospitals 6
   Only in research setting 1
   Not available 2
4. Explanations for limited genetic services?
   Lack of finances 5
   Lack of interest/knowledge 4
   Lack of geneticists/genetic counsellors 1
5. Strategies for identification of LS?
   Clinical criteria, i.e., Amsterdam II criteria or Revised Bethesda guidelines 8
   Universal screening of all new CRC or endometrial cancer 1
6. Are most LS families identified?
   Most not identified 11
   Most identified 1
7. Is surveillance offered?
   Colonoscopic surveillance? 11
   Endometrial surveillance? 5
   Urinary tract? 3
   Upper GI tract? 5
   Helicobacter Pylori assessment? 4
8. Surgical treatment:
   Subtotal colectomy offered to patients with CRC < 50 years 6
9. Lynch syndrome Registry available? 7
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The current survey is the first study to provide informa-
tion on prevailing LS healthcare in the ME/NA countries. 
The survey revealed that a family history of CRC receives 
appropriate attention in fewer than half the countries, and 
guidelines for the management of LS are available in only 
three of the 12 countries surveyed. The identification and 
selection of families for further genetic testing were gener-
ally based on clinical criteria, i.e., the Amsterdam criteria 
II or Revised Bethesda criteria, but universal screening was 
performed in one country. Genetic services are limited to 
only a few hospitals or a research setting in most countries. 
The surveillance offered in the majority of countries consists 
of regular colonoscopy, 1x/2 years, from age 20–25 years, 
while screening of the endometrium is available in less than 
half of the countries surveyed. In seven countries, a Heredi-
tary Cancer Registry is available.
Ten years ago, a similar survey based on 30 respondents 
was performed in 14 European countries [11]. The results 
indicated that most countries devoted sufficient attention to 
a family history of CRC, although the quality of the obtained 
family history was considered suboptimal in some countries. 
Guidelines for the management of LS were available in most 
of the countries surveyed at that time. In addition, clini-
cal criteria were mainly used for the selection of families 
for genetic testing (in all but one country), which is simi-
lar to the current survey. Nowadays, universal screening of 
all newly detected cases of CRC and endometrial cancer is 
recommended in the national guidelines of most European 
countries.
Another comprehensive survey of worldwide patterns of 
practice in the diagnosis and management of Lynch syn-
drome was performed recently by the International Mis-
match Repair Consortium (IMRC)[12]. Data were collected 
from institutions in 21 countries (55 respondents) in Europe, 
North, Central and South America, Asia and Australasia. 
ME/NA countries were not included. Fifty-five percent of 
the respondents reported routine screening of newly identi-
fied LS-related cancers, and 27% reported relying on clinical 
criteria together with selective tumour testing and germline 
analysis. Most institutions (64%) also reported the use of 
multigene panels. Reported risk management practices 
included 1–2 yearly colonoscopy in almost all programs 
(98%) and gynaecological screening in 78%. Gastric cancer 
screening was recommended in 56% of programs, especially 
so in Asia, North, Central and South America. The authors 
concluded that there is widespread heterogeneity in manage-
ment practices for LS worldwide, which is probably due to 
the rapid pace of emerging technology and regional differ-
ences in resources.
A major strength of the survey is the large number of 
participating countries which taken together represent a 
population of 390 million people (Table 1). A concurrent 
limitation was the relatively low number of respondents 
from each country, which is probably attributable to a lack 
of awareness or interest in LS in these countries.
What are the implications of the results of this survey? 
In view of the finding that most families with LS in ME/
NA countries probably remain unidentified, the first and 
foremost question is how the recognition of these families 
might be improved and which tools should be used. In this 
respect, we must recognize that the economic outlook is 
poor in most of the included countries and therefore the best 
approach will likely vary between countries and depend on 
the available (financial) resources. Regardless of the eco-
nomic situation, obtaining a detailed family history of (colo-
rectal) cancer could be easily implemented in all countries. 
A detailed family history requires asking whether cancer 
occurs in first- and second-degree relatives, including the 
type of cancer and the age at diagnosis [11, 13]. Online risk 
assessment tools can be used to assist with risk stratification 
and the management of patient and family screening [13]. In 
countries with limited financial resources, clinical criteria 
such as the revised Bethesda criteria can be used to select 
families for molecular testing of tumours, which is usually 
based on IHC analysis of the MMR proteins. In these coun-
tries, obtaining an appropriate family history is particularly 
important as it is essential to determine whether the clinical 
criteria have been met. In countries with sufficient financial 
resources, universal screening with IHC testing of all newly 
detected CRC and endometrial cancer below age 70 (or inde-
pendent of age) is probably the best approach [14], although 
the cost-effectiveness of this approach in ME/NA countries 
remains to be determined.
For successful implementation of tumour analysis and 
subsequent germline analysis, a well-established infrastruc-
ture is needed. One of the reasons why genetic services are 
limited is that clinical geneticists or genetic counsellors are 
scarce in many countries. In view of the remarkable progress 
of genetic testing across a wide area of medicine, training of 
more geneticists and genetic counsellors should be promoted 
in all ME/NA countries and more attention should be paid to 
genetics in all medical curricula. In the interim, training of 
current healthcare professionals regarding hereditary cancer 
and genetic counselling should be organized, for example via 
e-learning modules [15]. In addition, an online forum could 
further assist the establishment of infrastructure through the 
use of shared resources as well as forming a supportive pro-
fessional network to share experiences and opinions.
Registries of families with inherited cancer should also 
be established, with the aim of encouraging participation 
in prevention programs and to guarantee the continuity of 
lifetime surveillance programs [16].
Another key issue is the need to increase awareness of 
the importance of hereditary factors in the development of 
cancer amongst the general population as well as doctors. 
Information pamphlets for patients with (colorectal) cancer 
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should contain a paragraph about hereditary cancer and the 
need for preventative measures in case of confirmed heredi-
tary cancer. This information should also be provided on 
hospital websites accessible to the general public. To help 
improve knowledge about hereditary cancer among physi-
cians in ME/NA countries, all major scientific conferences 
concerning CRC should include sessions on hereditary CRC, 
including polyposis and Lynch syndrome. In addition, guide-
lines should be developed that correspond to the specific 
situation in a country.
A further suggestion to help raise awareness of hereditary 
conditions among the public and healthcare professionals 
is the engagement of charities and non-profit governmental 
organisations to support and promote policy change. These 
organisations can also aid in the development of screening 
programmes, as well as universal genetic screening strate-
gies for Lynch syndrome.
In conclusion, the current study shows that the identifica-
tion and management of LS in ME/NA countries is still sub-
optimal. Future efforts should focus on increasing awareness 
of LS amongst both the general population and doctors, and 
on improvement of the infrastructure in these countries. A 
summary of our recommendations to improve LS care can 
be found in Table 3.
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